GMP Clearance Routes and Product Classification under Thailand's Regulatory Framework for Imported Pharmaceuticals: A Documentary Analysis of Requirements for Indian Manufacturing Sites

Authors

  • Ashwitha Erukulla Student, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co.Ed), Tarnaka, India, 500017.
  • Srinivas Nimmagadda Professor. Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co.Ed), Tarnaka, India,
  • Abhilash Gattu Assistant Manger ,Exports, Leads Pharma Ltd, Hyderabad.
  • Saisree Sakinala Student, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co.Ed), Tarnaka, India, 500017.
  • Medishetti Swetha Professor. Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co.Ed), Tarnaka, India .

Keywords:

Thailand Food and Drug Administration (TFDA), Good Manufacturing Practice (GMP), Indian Pharmaceutical Exports, ASEAN Common Technical Dossier (ACTD), Pharmaceutical Regulation, Product Classification

Abstract

The export of pharmaceutical products from India to Southeast Asian markets, particularly Thailand, has grown significantly due to India's cost-effective manufacturing capabilities, advanced chemical synthesis, and strong generic drug industry. However, entering the Thai pharmaceutical market requires strict compliance with regulatory requirements established by the Thai Food and Drug Administration (TFDA) under the Drug Act B.E. 2510 (1967) and its subsequent amendments, including Drug Act (No. 6) B.E. 2562. This study examines the regulatory framework governing pharmaceutical imports from India into Thailand, focusing on product classification, Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) requirements, Site Master File (SMF) assessment, and ASEAN Common Technical Dossier (ACTD) submission procedures. It also evaluates stability testing requirements under ASEAN Climatic Zone IVb conditions (30°C ± 2°C / 75% RH ± 5% RH). Particular attention is given to regulatory challenges, including differences between India's Revised Schedule M and PIC/S GMP standards, product misclassification, dossier deficiencies, data integrity under ALCOA+ principles, computerized system validation, bioequivalence study requirements, and post-approval variations. The analysis highlights the importance of facility gap assessments, quality risk management, accurate regulatory documentation, and coordination with Thai Marketing Authorization Holders (MAHs). It emphasizes that compliance with TFDA requirements, regional harmonization standards, and international quality guidelines is essential for successful market entry. Overall, this study proposes a comprehensive regulatory compliance strategy to help Indian pharmaceutical manufacturers overcome regulatory barriers, reduce import delays, strengthen supply chain efficiency, and achieve sustainable commercial access to Thailand's pharmaceutical market.

Downloads

Download data is not yet available.

References

1. World Health Organization. Global report on the regulation of medical products: reaching for quality. Geneva: World Health Organization; 2021.

2. Thai Food and Drug Administration. Drug Act B.E. 2510 (1967) and subsequent amendments (Drug Act No. 6 B.E. 2562). Nonthaburi: Ministry of Public Health, Thailand; 2019. https://www.fda.moph.go.th/

3. Pharmaceutical Inspection Co-operation Scheme (PIC/S). Guide to good manufacturing practice for medicinal products (PE 009-16). Geneva: PIC/S Secretariat; 2022. https://picscheme.org/en/publications

4. Thai Food and Drug Administration. Guidelines on SKYNET e-submission and overseas manufacturing site GMP clearance procedures for imported pharmaceuticals. Nonthaburi: Medicine Regulation Division, TFDA; 2023.https://www.fda.moph.go.th/

5. Association of Southeast Asian Nations (ASEAN). ASEAN Common Technical Dossier (ACTD) for the registration of pharmaceuticals for human use and ASEAN variation guidelines. Jakarta: ASEAN Secretariat; 2018. https://asean.org/

6. Central Drugs Standard Control Organization (CDSCO). Revised Schedule M: Good manufacturing practices and requirements of premises, plant and equipment for pharmaceutical products (G.S.R. 922(E)). New Delhi: Ministry of Health and Family Welfare, Government of India; 2023. https://cdsco.gov.in/

7. International Council for Harmonisation (ICH). ICH harmonised guideline: quality risk management Q9(R1). Geneva: ICH Secretariat; 2023. https://www.ich.org/

8. Pharmexcil. Export performance report and regulatory compliance handbook for ASEAN pharmaceutical markets. Hyderabad: Pharmaceuticals Export Promotion Council of India; 2025. https://pharmexcil.com/

9. Artixio. Pharmaceutical regulations, product classification, and registration in Thailand: Market entry guide. London: Artixio Regulatory Intelligence; 2023. https://artixio.com/

10. Credevo. New and generic drug registration process in Thailand: A guide to commercial market entry and deficiency management. Singapore: Credevo Healthcare Insights; 2023. https://credevo.com/

11. PharmaTradz. Sourcing active pharmaceutical ingredients (APIs) and contract manufacturing regulatory compliance in Thailand. Bangkok: PharmaTradz Global Insights; 2026. https://pharmatradz.com/

12. ASEAN Secretariat. ASEAN Guideline on Stability Study of Drug Product (Revision 2). Understanding Climatic Zone IVb (30°C/75% RH) requirements.

Downloads

Published

2026-11-08

How to Cite

Erukulla, A., Nimmagadda, S., Gattu, A., Sakinala, S., & Medishetti, S. (2026). GMP Clearance Routes and Product Classification under Thailand’s Regulatory Framework for Imported Pharmaceuticals: A Documentary Analysis of Requirements for Indian Manufacturing Sites. Journal of Comprehensive Pharmaceutical Sciences , 1(2), 46–53. Retrieved from https://cognixpress.in/index.php/jcps/article/view/90

Issue

Section

Articles